Skip to main content
SpringerLink
Log in

The Biologic Basis of Cancer Chemotherapy

  • Chapter
Surgical Oncology

  • 234 Accesses

Abstract

The treatment of cancer with antineoplastic drugs has improved tremendously since the discovery over 40 years ago that nitrogen mustard can palliate advanced malignancies. Curative therapy is now available for such cancers as acute leukemia, testicular carcinoma, and aggressive non-Hodgkin’s lymphoma, while substantial prolongation of life is possible for patients with many other forms of cancer. Although many of the ways in which the anticancer drugs are used have evolved empirically over the last four decades, our understanding of the biologic principles underlying cancer chemotherapy has increased as well, providing the foundation for more effective cancer treatment in the future.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Anonymous (1983) Sequential methotrexate and 5-fluorouracil in the management of neoplastic disease. Semin Oncol 10 [Suppl 2]: 1–39

    Google Scholar 

  • Baylin SB, Gazdar AF, Minna JD, Bernal SD, Shaper JH (1982) A unique cell surface protein phenotype distinguishes human small-cell from non-small cell lung cancer. Proc Natl Acad Sci USA 79: 4650–4654

    Article  PubMed  CAS  Google Scholar 

  • Blum RH, Carter SK, Agre K (1973) A clinical review of bleomycin: a new antineoplastic agent. Cancer 31: 903–913

    Article  PubMed  CAS  Google Scholar 

  • Bonadonna G, Valagussa P (1981) Dose response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 30: 10–15

    Article  Google Scholar 

  • Bonadonna G, Valagussa P, Santoro A (1986) Alternating non-cross-resistant combination chemotherapy or MOPP in Stage IV Hodgkin’s disease. Ann Intern Med 104: 739–746

    PubMed  CAS  Google Scholar 

  • Brower M, Loughner J (1985) Cancer chemotherapy, part 1: the alkylating agents. Hosp Formul 20: 1060–1070

    Google Scholar 

  • Brower M, Ihde DC, Johnston-Early A et al. (1983) Treatment of extensive stage small cell bronchogenic carcinoma: effects of variation in intensity of induction chemotherapy. Am J Med 75: 993–1000

    Article  PubMed  CAS  Google Scholar 

  • Carney DN, Winkler CF (1985) In vitro assays of chemother-apeutic sensitivity. In: De Vita VT, Hellman S, Rosenberg SA (eds) Important advances in oncology 1985. Lippincott, Philadelphia

    Google Scholar 

  • Carney DN, Ahluwalia GS, Jayaram HN, Cooney DA, Johns DG (1985) Relationship between the cytotoxicity of tiazofu-rin and its metabolism by cultured human lung cancer cells. J Clin Invest 75: 175–182

    Article  PubMed  CAS  Google Scholar 

  • Cersosimo RJ, Hong WK (1986) Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an ad-riamycin analog. J Clin Oncol 4: 425–439

    PubMed  CAS  Google Scholar 

  • Chabner B (1982) Pharmacologic principles of cancer treatment. Saunders, Philadelphia

    Google Scholar 

  • Curt GA, Carney DN, Cowan KH et al. (1983) Unstable methotrexate resistance in human small cell carcinoma associated with double minute chromosomes. N Engl J Med 308: 199–202

    Article  PubMed  CAS  Google Scholar 

  • Curt GA, Jolivet J, Carney DN et al. (1985) Determinants of the sensitivity of human small cell lung cancer cell lines to methotrexate. J Clin Invest 76: 1323–1329

    Article  PubMed  CAS  Google Scholar 

  • Driscoll JS (1984) The preclinical and new drug research program of the National Cancer Institute. Cancer Treat Rep 68: 63–76

    PubMed  CAS  Google Scholar 

  • Frei E, Canellos GP (1980) Dose: a critical factor in cancer chemotherapy. Am J Med 69: 585–594

    Article  PubMed  Google Scholar 

  • Goldie JH, Coldman AJ (1979) A mathematical model relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63: 1727–1733

    PubMed  CAS  Google Scholar 

  • Goldie JH, Coldman AJ (1983) Quantitative model for multiple levels of drug resistance in clinical tumors. Cancer Treat Rep 67: 923–931

    PubMed  CAS  Google Scholar 

  • Grem JL, Hoth DF, Hamilton JM, King SA, Leyland-Jones B (1987) Overview of current status and future direction of clinical trials with 5-fluorouracil in combination with folinic acid. Cancer Treat Rep 71: 1249–1264

    PubMed  CAS  Google Scholar 

  • Gros P, Croop J, Housman D (1986) Mammalian multidrug resistance gene: complete cDNA sequence indicates strong homology to bacterial transport proteins. Cell 47: 371–380

    Article  PubMed  CAS  Google Scholar 

  • Guild BC, Mulligan RC, Gros P, Housman DE (1988) Retroviral transfer of a murine cDNA for multidrug resistance confers pleiotropic drug resistance to cells without prior drug selection. Proc Natl Acad Sci USA 85: 1595–1599

    Article  PubMed  CAS  Google Scholar 

  • Johnson GJ, Costello WB, Oken MM et al. (1983) Sequential cyclophosphamide–prednisone and vincristine-bleomycin (CPOB): an effective schedule-dependent treatment for advanced diffuse histiocytic lymphoma. Cancer 52: 1133–1141

    Article  PubMed  CAS  Google Scholar 

  • Jolivet J, Cowan KH, Curt GA, Clendeninn NJ, Chabner BA (1983) The pharmacology and clinical use of methotrexate. N Engl J Med 309: 1094–1104

    Article  PubMed  CAS  Google Scholar 

  • Klein G, Klein E (1985) Evolution of tumors and the impact of molecular oncology. Nature 315: 190–195

    Article  PubMed  CAS  Google Scholar 

  • Klimo P, Connors JM (1985) MACOP-B chemotherapy for the treatment of diffuse large cell lymphoma. Ann Intern Med 102: 596–602

    PubMed  CAS  Google Scholar 

  • Krakoff IH (1981) Cancer chemotherapeutic agents. CA 31: 130–140

    CAS  Google Scholar 

  • Ling V, Kartner N, Sudo T, Siminovitch L, Riordan JR (1983) Multidrug resistance phenotype in Chinese hamster ovary cells. Cancer Treat Rep 67: 869–874

    PubMed  CAS  Google Scholar 

  • Loehrer PJ, Einhorn LH (1984) Cisplatin. Ann Intern Med 100:704–713

    PubMed  CAS  Google Scholar 

  • Norton L, Simon R (1986) The Norton-Simon hypothesis revisited. Cancer Treat Rep 70: 163–169

    PubMed  CAS  Google Scholar 

  • Ozols RF, Cowan K (1986) New aspects of clinical drug resistance: the role of gene amplification and the reversal of resistance in drug refractory cancer. In: De Vita VT, Hellman S, Rosenberg SA (eds) Important advances in oncology 1986. Lippincott, Philadelphia, pp 129–157

    Google Scholar 

  • Ozols RF, Corden BJ, Jacobs J, Wesley MN, Ostchega Y, Young RC (1984) High-dose cisplatin in hypertonic saline. Ann Intern Med 100: 19–24

    PubMed  CAS  Google Scholar 

  • Pratt WB, Ruddon RW (1979) The anticancer drugs. Oxford University Press, New York

    Google Scholar 

  • Ross W, Rowe T, Glisson J, Yalowich J, Liu L (1984) Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage. Cancer Res 44: 5857–5860

    PubMed  CAS  Google Scholar 

  • Selby P, Buick RN, Tannock I (1983) A critical appraisal of the “human tumor stem-cell assay”. N Engl J Med 308: 129–134

    Article  PubMed  CAS  Google Scholar 

  • Shenkenberg TD, Van Hoff DD (1986) Mitoxantrone: a new anticancer drug with significant clinical activity. Ann Intern Med 105: 67–81

    PubMed  CAS  Google Scholar 

  • Shoemaker RH (1986) New approaches to antitumor drug screening: the human tumor colony forming assay. Cancer Treat Rep 70: 9–12

    PubMed  CAS  Google Scholar 

  • Tannock I (1978) Cell kinetics and chemotherapy: a critical review. Cancer Treat Rep 62: 1117–1133

    PubMed  CAS  Google Scholar 

  • Tsuruo T (1983) Reversal of acquired resistance to vinca alka* loids and anthracycline antibiotics. Cancer Treat Rep 67: 889–894

    PubMed  CAS  Google Scholar 

  • Weiss RB, Issell BF (1982) The nitrosoureas: carmustine (BCNU) and lomustine (CCNU). Cancer Treat Rev 9: 313–330

    Article  PubMed  CAS  Google Scholar 

  • Young RC, Ozols RF, Myers CE (1981) The anthracycline antineoplastic drugs. N Engl J Med 305: 139–153

    Article  PubMed  CAS  Google Scholar 

  • Zimm S, Collins JM, Riccardi R et al. (1983) Variable bioavailability of oral mercaptopurine. N Engl J Med 308: 1005–1009

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. M. Brower
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Carney
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian, 1, 20133, Milano, Italy

    Umberto Veronesi (Direttore Generale) (Direttore Generale)

  2. Department of Surgery, Haukeland University Hospital, University of Bergen, 5021, Bergen, Norway

    Bo Arnesjø

  3. Charing Cross Hospital, Fulham Palace Road, London, W6 8RF, UK

    Ian Burn

  4. Department of Urology, A.Z. Middelheim, Vrue Universiteit Brussel, Lindendreef 1, 2020, Antwerpen, Belgium

    Louis Denis

  5. Cattedra di Chirurgia Generale, II facolta’, Università di Napoli, Via Pansini, 5, 80131, Napoli, Italy

    Francesco Mazzeo

Rights and permissions

Reprints and permissions

Copyright information

© 1989 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Brower, M., Carney, D. (1989). The Biologic Basis of Cancer Chemotherapy. In: Veronesi, U., Arnesjø, B., Burn, I., Denis, L., Mazzeo, F. (eds) Surgical Oncology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-72646-0_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-72646-0_15

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-72648-4

  • Online ISBN: 978-3-642-72646-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation